申请人:Schering Aktiengesellschaft
公开号:US04731367A1
公开(公告)日:1988-03-15
Novel ergoline derivatives, substituted in the 2-position, of the formula ##STR1## wherein C.sub.8 -C.sub.9 and C.sub.9 -C.sub.10 each independently is a CC-single or a C.dbd.C-double bond, but not together a cumulated double bond, and the substituent in the 8-position is in the .alpha.- or .beta.-configuration where C.sub.8 -C.sub.9 is a CC-single bond, R.sup.2 is CN, SR, SOR, ##STR2## wherein n is 2 or 3, ##STR3## and --CH(OH)R, wherein R has the meaning of H or C.sub.1-4 -alkyl, the grouping COR' and CSR' wherein R'.dbd.OH, OC.sub.1-4 -alkyl, benzyl, NH.sub.2 or NHR", the grouping CH.dbd.CH--CO.sub.2 R" and CH.sub.2 --CH.sub.2 --CO.sub.2 R" wherein R".dbd.C.sub.1-4 -alkyl, the grouping C.vertline.C-R'" and HC.dbd.CH--R'" wherein R'".dbd. hydrogen, C.sub.1-4 -alkyl, phenyl, CH.sub.2 OH, CR".sub.2 OH, ##STR4## CO.sub.2 R", CH.sub.2 NR".sub.2 or SiMe.sub.2 R"; C.sub.1-3 -alkyl, or C.sub.1-3 -alkyl substituted by OH or phenyl; or ##STR5## wherein R" is C.sub.1-4 alkyl, R.sup.6 is C.sub.1-4 -alkyl and R.sup.8 is methyl, NH--CO--NEt.sub.2 or NH--CS--NEt.sub.2, and the physiologically acceptable acid addition salt thereof, possess biological efficacy in the region of the central nervous system, e.g., as neuroleptics and anti-depressants.
新颖的麦角酸衍生物,其在2-位置被取代,化学式为##STR1##其中C.sub.8-C.sub.9和C.sub.9-C.sub.10各自独立地是CC-单键或C.dbd.C-双键,但不是一个累积的双键,而8-位置的取代基处于α-或β-构型,其中C.sub.8-C.sub.9是CC-单键,R.sup.2是CN、SR、SOR、##STR2##其中n为2或3,##STR3##和--CH(OH)R,其中R具有H或C.sub.1-4-烷基的含义,包括羟甲酰基COR'和硫醇甲酰基CSR',其中R'.dbd.OH、OC.sub.1-4-烷基、苄基、NH.sub.2或NHR",包括CH.dbd.CH--CO.sub.2 R"和CH.sub.2--CH.sub.2--CO.sub.2 R"的群,其中R".dbd.C.sub.1-4-烷基,包括C.vertline.C-R'"和HC.dbd.CH--R'"的群,其中R'".dbd.氢、C.sub.1-4-烷基、苯基、CH.sub.2 OH、CR".sub.2 OH、##STR4##CO.sub.2 R"、CH.sub.2 NR".sub.2或SiMe.sub.2 R";C.sub.1-3-烷基,或被OH或苯基取代的C.sub.1-3-烷基;或##STR5##其中R"为C.sub.1-4-烷基,R.sup.6为C.sub.1-4-烷基,R.sup.8为甲基、NH--CO--NEt.sub.2或NH--CS--NEt.sub.2,以及其生理上可接受的酸盐,具有在中枢神经系统区域的生物学效应,例如,作为神经精神药和抗抑郁药。